日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study

瑞戈非尼用于不可切除肝细胞癌患者:REFINE观察性研究中特别关注亚组的分析

Kim, Y J; Merle, P; Finn, R S; Klümpen, H-J; Lim, H Y; Ikeda, M; Granito, A; Masi, G; Gerolami, R; Pinter, M; Babajanyan, S; Twumasi-Ankrah, P; Ghadessi, M; Ozgurdal, K; Qin, S

Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial

阿特珠单抗联合贝伐珠单抗一线治疗不可切除肝细胞癌:AMETHISTA IIIb期试验的中期分析结果

Piscaglia, F; Masi, G; Martinelli, E; Cabibbo, G; Di Maio, M; Gasbarrini, A; Iavarone, M; Antonuzzo, L; Mazzaferro, V; Ballestrero, A; Garufi, C; Bergamo, F; Celsa, C; Marino, D; Tovoli, F; Ponziani, F R; Pressiani, T; Astolfi, C; Gazzoli, G C; Ciardiello, F; Daniele, B; Rimassa, L

Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis

肝细胞癌基因组分析:一项真实世界回顾性分析

Salani, F; Ponziani, F R; Piscaglia, F; Malapelle, U; Daniele, B; Porta, C; Pradelli, L; De Fiore, E; Masi, G; Rimassa, L; Casadei Gardini, A

Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment

早期调整贝伐单抗的剂量和给药时间可能会影响阿特珠单抗联合贝伐单抗治疗晚期肝细胞癌的疗效。

Rossari, F; Lavacchi, D; Alimenti, E; Soldà, C; Salani, F; Esposito, L; Foti, S; Camera, S; Persano, M; Lo Prinzi, F; Vitiello, F; Pellegrini, E; Bruccoleri, M; Rizzato, M D; Caccese, M; Rapposelli, I G; Guidolin, A; De Rosa, A; Antonuzzo, L; Masi, G; Iavarone, M A; Lonardi, S; Rimini, M; Casadei-Gardini, A

Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience

预测最初无法切除的结直肠肝转移瘤切除术后的早期复发:基线和术前临床、影像学和分子因素在真实世界多中心研究中的作用

Moretto, R; Germani, M M; Borelli, B; Conca, V; Rossini, D; Boraschi, P; Donati, F; Urbani, L; Lonardi, S; Bergamo, F; Cerma, K; Ramondo, G; D'Amico, F E; Salvatore, L; Valente, G; Barbaro, B; Giuliante, F; Di Maio, M; Masi, G; Cremolini, C

Concordance of PD-L1 status in primary gastroesophageal adenocarcinoma and matched peritoneal metastases: a single institution study

原发性胃食管腺癌及其匹配的腹膜转移灶中PD-L1状态的一致性:一项单中心研究

Massa, V; Signorini, F; Salani, F; Filice, M E; Grelli, G; Lippolis, P; Faviana, P; Genovesi, V; Santi, S; Vivaldi, C; Cesario, S; Bertolucci, A; Cremolini, C; Nardini, V; Masi, G; Ugolini, C; Fornaro, L

Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials

西妥昔单抗作为三线再挑战治疗,联合伊立替康或阿维鲁单抗,对基线血浆RAS/BRAF野生型循环肿瘤DNA的转移性结直肠癌患者有效:CRICKET和CAVE试验的个体患者数据汇总分析

Martini, G; Ciardiello, D; Famiglietti, V; Rossini, D; Antoniotti, C; Troiani, T; Napolitano, S; Esposito, L; Latiano, T P; Maiello, E; Del Re, M; Lonardi, S; Aprile, G; Santini, D; Masi, G; Avallone, A; Normanno, N; Pietrantonio, F; Pinto, C; Ciardiello, F; Cremolini, C; Martinelli, E

PP088 The case fatality rate of COVID-19 infection in non-small cell lung cancer

PP088 非小细胞肺癌中 COVID-19 感染的病死率

Rimini, M; Rimassa, L; Ueshima, K; Burgio, V; Shigeo, S; Tada, T; Suda, G; Yoo, C; Cheon, J; Pinato, D J; Lonardi, S; Scartozzi, M; Iavarone, M; Di Costanzo, G G; Marra, F; Soldà, C; Tamburini, E; Piscaglia, F; Masi, G; Cabibbo, G; Foschi, F G; Silletta, M; Pressiani, T; Nishida, N; Iwamoto, H; Sakamoto, N; Ryoo, B-Y; Chon, H J; Claudia, F; Niizeki, T; Sho, T; Kang, B; D'Alessio, A; Kumada, T; Hiraoka, A; Hirooka, M; Kariyama, K; Tani, J; Atsukawa, M; Takaguchi, K; Itobayashi, E; Fukunishi, S; Tsuji, K; Ishikawa, T; Tajiri, K; Ochi, H; Yasuda, S; Toyoda, H; Ogawa, C; Nishimur, T; Hatanaka, T; Kakizaki, S; Shimada, N; Kawata, K; Tanaka, T; Ohama, H; Nouso, K; Morishita, A; Tsutsui, A; Nagano, T; Itokawa, N; Okubo, T; Arai, T; Imai, M; Naganuma, A; Koizumi, Y; Nakamura, S; Joko, K; Iijima, H; Hiasa, Y; Pedica, F; De Cobelli, F; Ratti, F; Aldrighetti, L; Kudo, M; Cascinu, S; Casadei-Gardini, A; Wanchaijiraboon, P; Teeyapun, N; Luangdilok, S; Wanlapakorn, N; Sainamthip, P; Pakvisal, N; Namkanisorn, T; Sriuranpong, V; Phaibulvatanapong, E; Veranitinun, R; Inthasuwan, P; Sartsuk, C; Phongwan, R; Angspatt, P; Wongchanapat, P; Poovorawan, Y; Tanasanvimon, S; Jung, YJ; Park, SH; Jung, HA; Sun, J-M; Lee, S-H; Ahn, JS; Ahn, M-J

Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials

TRIBE 和 TRIBE2 试验的亚组分析显示,接受双药或三药化疗联合贝伐单抗治疗的转移性结直肠癌患者,骨转移与预后不良相关:

Dell'Aquila, E; Rossini, D; Fulgenzi, C A M; Passardi, A; Tamburini, E; Vetere, G; Carullo, M; Citarella, F; Antoniotti, C; Zaniboni, A; Pietrantonio, F; Spagnoletti, A; Marmorino, F; Borelli, B; Allegrini, G; Lonardi, S; Nappo, F; Masi, G; Cremolini, C; Santini, D

Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma

通过递归分割分析法鉴定晚期肝细胞癌中乐伐替尼预后指数

Rapposelli, I G; Shimose, S; Kumada, T; Okamura, S; Hiraoka, A; Di Costanzo, G G; Marra, F; Tamburini, E; Forgione, A; Foschi, F G; Silletta, M; Lonardi, S; Masi, G; Scartozzi, M; Nakano, M; Shibata, H; Kawata, K; Pellino, A; Vivaldi, C; Lai, E; Takata, A; Tajiri, K; Toyoda, H; Tortora, R; Campani, C; Viola, M G; Piscaglia, F; Conti, F; Fulgenzi, C A M; Frassineti, G L; Rizzato, M D; Salani, F; Astara, G; Torimura, T; Atsukawa, M; Tada, T; Burgio, V; Rimini, M; Cascinu, S; Casadei-Gardini, A